Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/213190 |
Resumo: | The present study was carried out to evaluate the effect of Melatonin and Placebo in the patientwith the Burning mouth (BMs). This double-blind, placebo-controlled randomized clinical trialstudy was carried out on 30 patients who were suffering from BMS. During this period patientswere divided into 2 study and control groups. The study group used four 3 mg Melatonindaily and the control group received a placebo. Then the severity of the burning sensation wasmeasured by the physician Sleep quality was measured using the VAS scale using the Petersburgquestionnaire. Data in the application Enter SPSS 20 and then using T test or equivalentNonparametric was analyzed, mean sleep score and mean severity of oral irritation before andafter treatment in two the group was evaluated using T-test Independent. Level significance wasconsidered 0.05. The results of the present study show that the use of melatonin and a placeboin patients with BMS reduces sensation and improves their sleep quality, although it may notreduce it completely. In this study severity of burning was 4.93±2.56 after treatment in the studygroup and 6.93±2.12 in the control group, which was statistically significant (P =0.036). Nosignificant difference was observed between the two groups in the sleep quality score (P-value= 0.43). Using Melatonin can be a reliable way to treat pain for which there is no standardtreatment to date. Although evidence suggests an association between sleep disorders andBMS, melatonin was not superior to a placebo in reducing BMS-induced burning in the presentstudy. Identification of stressors and the ways to struggle with them, further studies with largersamples and higher oral doses, extended follow-up periods and control of psychological factors,and measurement of body mass index that may affect pharmacokinetics are recommended |
id |
USP-31_b6325b428d0377cfb95daad242050090 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/213190 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trialMelatoninBMSSleepThe present study was carried out to evaluate the effect of Melatonin and Placebo in the patientwith the Burning mouth (BMs). This double-blind, placebo-controlled randomized clinical trialstudy was carried out on 30 patients who were suffering from BMS. During this period patientswere divided into 2 study and control groups. The study group used four 3 mg Melatonindaily and the control group received a placebo. Then the severity of the burning sensation wasmeasured by the physician Sleep quality was measured using the VAS scale using the Petersburgquestionnaire. Data in the application Enter SPSS 20 and then using T test or equivalentNonparametric was analyzed, mean sleep score and mean severity of oral irritation before andafter treatment in two the group was evaluated using T-test Independent. Level significance wasconsidered 0.05. The results of the present study show that the use of melatonin and a placeboin patients with BMS reduces sensation and improves their sleep quality, although it may notreduce it completely. In this study severity of burning was 4.93±2.56 after treatment in the studygroup and 6.93±2.12 in the control group, which was statistically significant (P =0.036). Nosignificant difference was observed between the two groups in the sleep quality score (P-value= 0.43). Using Melatonin can be a reliable way to treat pain for which there is no standardtreatment to date. Although evidence suggests an association between sleep disorders andBMS, melatonin was not superior to a placebo in reducing BMS-induced burning in the presentstudy. Identification of stressors and the ways to struggle with them, further studies with largersamples and higher oral doses, extended follow-up periods and control of psychological factors,and measurement of body mass index that may affect pharmacokinetics are recommendedUniversidade de São Paulo. Faculdade de Ciências Farmacêuticas2023-06-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/21319010.1590/s2175-97902023e21748 Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023)Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/213190/195163Copyright (c) 2023 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessNosratzehi, Tahereh Payandeh, AbolfazlArbab, Kosar2023-06-15T14:56:44Zoai:revistas.usp.br:article/213190Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-06-15T14:56:44Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
title |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
spellingShingle |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial Nosratzehi, Tahereh Melatonin BMS Sleep |
title_short |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
title_full |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
title_fullStr |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
title_full_unstemmed |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
title_sort |
Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial |
author |
Nosratzehi, Tahereh |
author_facet |
Nosratzehi, Tahereh Payandeh, Abolfazl Arbab, Kosar |
author_role |
author |
author2 |
Payandeh, Abolfazl Arbab, Kosar |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Nosratzehi, Tahereh Payandeh, Abolfazl Arbab, Kosar |
dc.subject.por.fl_str_mv |
Melatonin BMS Sleep |
topic |
Melatonin BMS Sleep |
description |
The present study was carried out to evaluate the effect of Melatonin and Placebo in the patientwith the Burning mouth (BMs). This double-blind, placebo-controlled randomized clinical trialstudy was carried out on 30 patients who were suffering from BMS. During this period patientswere divided into 2 study and control groups. The study group used four 3 mg Melatonindaily and the control group received a placebo. Then the severity of the burning sensation wasmeasured by the physician Sleep quality was measured using the VAS scale using the Petersburgquestionnaire. Data in the application Enter SPSS 20 and then using T test or equivalentNonparametric was analyzed, mean sleep score and mean severity of oral irritation before andafter treatment in two the group was evaluated using T-test Independent. Level significance wasconsidered 0.05. The results of the present study show that the use of melatonin and a placeboin patients with BMS reduces sensation and improves their sleep quality, although it may notreduce it completely. In this study severity of burning was 4.93±2.56 after treatment in the studygroup and 6.93±2.12 in the control group, which was statistically significant (P =0.036). Nosignificant difference was observed between the two groups in the sleep quality score (P-value= 0.43). Using Melatonin can be a reliable way to treat pain for which there is no standardtreatment to date. Although evidence suggests an association between sleep disorders andBMS, melatonin was not superior to a placebo in reducing BMS-induced burning in the presentstudy. Identification of stressors and the ways to struggle with them, further studies with largersamples and higher oral doses, extended follow-up periods and control of psychological factors,and measurement of body mass index that may affect pharmacokinetics are recommended |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06-15 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/213190 10.1590/s2175-97902023e21748 |
url |
https://www.revistas.usp.br/bjps/article/view/213190 |
identifier_str_mv |
10.1590/s2175-97902023e21748 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/213190/195163 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023) Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023) Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023) 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222918141018112 |